WO2008120744A1 - ５員環アミド化合物およびその用途 - Google Patents

５員環アミド化合物およびその用途 Download PDF

Info

Publication number
WO2008120744A1
WO2008120744A1 PCT/JP2008/056173 JP2008056173W WO2008120744A1 WO 2008120744 A1 WO2008120744 A1 WO 2008120744A1 JP 2008056173 W JP2008056173 W JP 2008056173W WO 2008120744 A1 WO2008120744 A1 WO 2008120744A1
Authority
WO
WIPO (PCT)
Prior art keywords
amide compound
membered cyclic
cyclic amide
compound
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056173
Other languages
English (en)
French (fr)
Inventor
Tetsuya Iida
Minoru Ubukata
Ikuo Mitani
Yuichi Nakagawa
Masahiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of WO2008120744A1 publication Critical patent/WO2008120744A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　優れたＳＣＤ１活性阻害作用を有する化合物を提供すること。下記一般式［Ａ－１’］で表される化合物又はその医薬上許容される塩、或いはその溶媒和物： ［式中、各記号は明細書中で定義した通りである。］。
PCT/JP2008/056173 2007-03-30 2008-03-28 ５員環アミド化合物およびその用途 Ceased WO2008120744A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-095470 2007-03-30
JP2007095470 2007-03-30
US92580307P 2007-04-23 2007-04-23
US60/925,803 2007-04-23

Publications (1)

Publication Number Publication Date
WO2008120744A1 true WO2008120744A1 (ja) 2008-10-09

Family

ID=39808324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056173 Ceased WO2008120744A1 (ja) 2007-03-30 2008-03-28 ５員環アミド化合物およびその用途

Country Status (1)

Country Link
WO (1) WO2008120744A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009106203A1 (en) * 2008-02-25 2009-09-03 Merck Patent Gmbh Glucokinase activators
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12180221B2 (en) 2018-03-23 2024-12-31 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0324066A (ja) * 1989-06-14 1991-02-01 Bayer Ag ２‐アシルアミノ‐４‐ハロゲノ‐５‐ニトロチアゾール誘導体、その製造方法、殺有害生物剤としてのその利用、および新規中間体
WO2007022258A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
WO2008044767A1 (en) * 2006-10-13 2008-04-17 Takeda Pharmaceutical Company Limited Aromatic amine derivative and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0324066A (ja) * 1989-06-14 1991-02-01 Bayer Ag ２‐アシルアミノ‐４‐ハロゲノ‐５‐ニトロチアゾール誘導体、その製造方法、殺有害生物剤としてのその利用、および新規中間体
WO2007022258A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
WO2008044767A1 (en) * 2006-10-13 2008-04-17 Takeda Pharmaceutical Company Limited Aromatic amine derivative and use thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014208665A (ja) * 2008-02-25 2014-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ グルコキナーゼ活性化剤
WO2009106203A1 (en) * 2008-02-25 2009-09-03 Merck Patent Gmbh Glucokinase activators
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US12433880B2 (en) 2017-01-06 2025-10-07 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US10973810B2 (en) 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US12275723B2 (en) 2017-10-24 2025-04-15 Janssen Pharmaceutica Nv Compounds and uses thereof
US12180221B2 (en) 2018-03-23 2024-12-31 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof

Similar Documents

Publication Publication Date Title
WO2008120759A1 (ja) ウレア化合物およびその用途
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2008120744A1 (ja) ５員環アミド化合物およびその用途
PH12012501689A1 (en) 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv intergrase inhibitor
TW200732336A (en) Alyphactic heterocyclic compounds
WO2009048101A1 (ja) アミド化合物
MY146923A (en) Novel piperazine compound, and use thereof as hcv polymerase inhibitor
WO2009051244A1 (ja) 複素環化合物
WO2009060835A8 (ja) 新規ユビキリン結合性小分子
WO2007135527A3 (en) Benzimidazolyl compounds
PH12012501711A1 (en) [5,6] heterocyclic compound
WO2009154300A3 (en) Heterocyclic compound and use thereof
WO2008011130A3 (en) Amide compounds
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2008011131A3 (en) Amide compounds
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
TW200716541A (en) The preparation and use of compounds as protease inhibitors
WO2009028655A1 (ja) 複素環化合物およびその用途
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
MX2009013730A (es) Compuesto amina y uso farmaceutico del mismo.
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
MX2009008756A (es) Compuesto macrociclico.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739291

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08739291

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP